Celcuity (CELC) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Celcuity (CELC) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 33.7% versus a loss of 7.0%. Over five years, CELC leads with a +261.4% price change compared with +8.2% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.53 billion vs $3.22 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | XENE |
|---|---|---|
| Share price | $65.78 | $36.41 |
| Market cap | $3.22B | $3.53B |
| 1-day change | -7.68% | -0.44% |
| YTD return | -34.05% | -18.76% |
| 1-year return | +33.66% | -7.02% |
| 5-year return | +261.43% | +8.17% |
| EPS (TTM) | $-4.17 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $72.66 |
| 52-week low | $45.03 | $35.75 |
| Distance from 52-week high | -56.44% | -49.89% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +101.51% |
| Average volume | 1.19M | 1.47M |
| Shares outstanding | 48.93M | 96.84M |
| Employees | 155 | 358 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELC has outperformed XENE by 40.7 percentage points over the past year.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
CELC vs XENE FAQ
Which is bigger, Celcuity or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.53B compared with $3.22B for Celcuity (CELC).
Which stock has performed better over the past year, CELC or XENE?
CELC returned +33.66% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Xenon Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Pharmaceutical Preparations for Xenon Pharmaceuticals.